Condition (MeSH)
Iron Overload
ClinicalTrials.gov lists 184 trials for Iron Overload or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 31.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
141 of the 184 trials are tagged with Iron Overload itself; the rest are tagged with a narrower condition beneath it.
When did Iron Overload trials start? (31)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Expanded access)
Top of scale: 14
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 2 |
| 2024 | 5 |
| 2023 | 5 |
| 2022 | 4 |
| 2021 | 2 |
| 2020 | 7 |
| 2019 | 8 |
| 2018 | 5 |
| 2017 | 5 |
Showing 10 of 31 earlier years.
No forecast is made for this condition: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 34 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 35 months across 135 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Iron Overload trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 9 |
| Phase 1/2 | 3 |
| Phase 2 | 39 |
| Phase 2/3 | 4 |
| Phase 3 | 17 |
| Phase 4 | 19 |
| Not applicable | 29 |
| Observational | 63 |
| Expanded access | 1 |
How many Iron Overload trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 10 |
| Active, not recruiting | 4 |
| Completed | 127 |
| Approved for marketing | 1 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Iron Overload trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 31 |
| ApoPharma | 6 |
| National Heart, Lung, and Blood Institute (NHLBI) | 5 |
| Shire | 3 |
| Bond Biosciences | 2 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Iron Overload? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| SPD602 | 4 |
| SP-420 | 3 |
| Iron | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Deferasirox FCT | 40 |
| Deferoxamine mesylate only | 15 |
| Deferiprone pill | 13 |
| Amlodipine | 2 |
| BBI-001 | 2 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Iron Overload trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Sickle cell anaemia with crisis | 169 | 6 |
| Pyrexia | 128 | 18 |
| Pneumonia | 57 | 15 |
| Gastroenteritis | 39 | 10 |
| Abdominal pain | 38 | 8 |
Showing 5 of 10 adverse events.
Which publications cover Iron Overload? (251)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Multicenter, multivendor validation of liver quantitative susceptibility mapping in patients with iron overload at 1.5 T and 3 T. | Magnetic resonance in medicine | 2025 | Yes |
| Oxidative stress markers and tissue iron overload after 12-months vitamin E supplementation for children with transfusion-dependent β-thalassemia on different iron chelators: A randomized placebo-controlled trial. | Clinical nutrition (Edinburgh, Scotland) | 2025 | Yes |
| Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency. | Blood advances | 2024 | Yes |
| Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia. | The Cochrane database of systematic reviews | 2023 | Yes |
| Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years. | Blood advances | 2023 | Yes |
Showing 5 of 251 publications.
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.